<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02145013</url>
  </required_header>
  <id_info>
    <org_study_id>LIM Chetana</org_study_id>
    <nct_id>NCT02145013</nct_id>
  </id_info>
  <brief_title>Portal Hypertension and Liver Resection in Patients With Hepatocellular Carcinoma</brief_title>
  <official_title>Assessment and Impact of Portal Hypertension Before and During Liver Resection in Patients With Hepatocellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Henri Mondor University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Henri Mondor University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      According to the BCLC guidelines, surgical resection of hepatocellular carcinoma complicating
      cirrhosis is restricted to patients with preserved liver function, single nodule without
      vascular invasion and with hepatic venous gradient below 10 mmHg.

      However, other guideline treatment, especially from eastern countries demonstrated that
      surgical resection is safe and feasible and provides better survival than the treatment
      recommended by the BCLC system for patients with similar stage.

      The primary goal of this study is to assess the impact of HVPG on short and long-term
      outcomes in HCC patients who undergo liver resection.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with HCC and candidates for hepatectomy are classified into two groups according to
      the presence of portal hypertension. Short- and long-term outcomes will be compared.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Anticipated">May 30, 2018</completion_date>
  <primary_completion_date type="Actual">December 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Mortality</measure>
    <time_frame>90 day</time_frame>
    <description>In-hospital or 90-day mortality</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>morbidity</measure>
    <time_frame>90 day</time_frame>
    <description>Overall and liver-related complications including liver failure, ascites, biliary fistula, bleeding, pulmonary complications, and renal complications.
Grading system according to Clavien-Dindo classification</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival outcomes</measure>
    <time_frame>1,3 and 5 years</time_frame>
    <description>Including Overall survival and disease free survival</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Acute kidney injury</measure>
    <time_frame>within 90 days after surgery</time_frame>
    <description>As defined by the KDIGIO criteria</description>
  </other_outcome>
  <other_outcome>
    <measure>Sarcopenia</measure>
    <time_frame>Before liver resection</time_frame>
    <description>using computed tomography</description>
  </other_outcome>
  <other_outcome>
    <measure>Time from diagnosis to liver resection</measure>
    <time_frame>from the date of diagnosis until the date of first referral and from the date of first referral to date of hepatectomy, assessed up to 3 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Impact of PET CT on overall survival following liver resection</measure>
    <time_frame>Before liver resection</time_frame>
    <description>quantitative assessment of metabolic uptake (FDG and choline)</description>
  </other_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Primary Liver Cancers</condition>
  <arm_group>
    <arm_group_label>Portal hypertension</arm_group_label>
    <description>Hepatectomy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No portal hypertension</arm_group_label>
    <description>Hepatectomy</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Liver resection</intervention_name>
    <description>Hepatectomy by either open, laparoscopic or robotic procedures</description>
    <arm_group_label>Portal hypertension</arm_group_label>
    <arm_group_label>No portal hypertension</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All patients with hepatocellular carcinoma
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Patients with hepatocellular carcinoma who undergo surgical resection (intention to treat
        analysis)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel Azoulay, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Henri Mondor</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Henri Mondor University Hospital</name>
      <address>
        <city>Creteil</city>
        <zip>94000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Ishizawa T, Hasegawa K, Aoki T, Takahashi M, Inoue Y, Sano K, Imamura H, Sugawara Y, Kokudo N, Makuuchi M. Neither multiple tumors nor portal hypertension are surgical contraindications for hepatocellular carcinoma. Gastroenterology. 2008 Jun;134(7):1908-16. doi: 10.1053/j.gastro.2008.02.091. Epub 2008 Mar 8.</citation>
    <PMID>18549877</PMID>
  </reference>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 20, 2014</study_first_submitted>
  <study_first_submitted_qc>May 20, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 22, 2014</study_first_posted>
  <last_update_submitted>February 8, 2018</last_update_submitted>
  <last_update_submitted_qc>February 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Henri Mondor University Hospital</investigator_affiliation>
    <investigator_full_name>Chetana LIM</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>portal hypertension, hepatocellular carcinoma, resection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
    <mesh_term>Hypertension, Portal</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

